198 related articles for article (PubMed ID: 29525885)
1. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
[TBL] [Abstract][Full Text] [Related]
3. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
Divino V; DeKoven M; Khan FA; Boye KS; Sapin H; Norrbacka K
Diabetes Ther; 2017 Feb; 8(1):115-128. PubMed ID: 28070733
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
Divino V; DeKoven M; Hallinan S; Varol N; Wirta SB; Lee WC; Reaney M
Diabetes Ther; 2014 Dec; 5(2):499-520. PubMed ID: 25366334
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Wang J; Jin X; An P; Yu S; Mu Y
J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945
[TBL] [Abstract][Full Text] [Related]
10. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
13. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
[TBL] [Abstract][Full Text] [Related]
14. Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.
Lee J; Kim R; Kim MH; Lee SH; Cho JH; Lee JM; Jang SA; Kim HS
Prim Care Diabetes; 2023 Oct; 17(5):460-465. PubMed ID: 37541792
[TBL] [Abstract][Full Text] [Related]
15. Exenatide extended-release; clinical trials, patient preference, and economic considerations.
Doggrell SA
Patient Prefer Adherence; 2013; 7():35-45. PubMed ID: 23341736
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
19. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
[TBL] [Abstract][Full Text] [Related]
20. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.
Uccellatore A; Genovese S; Dicembrini I; Mannucci E; Ceriello A
Diabetes Ther; 2015 Sep; 6(3):239-56. PubMed ID: 26271795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
